

Yasuo Terauchi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6641081/yasuo-terauchi-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

160
papers

5,172
citations

31
h-index

69
g-index

178
ext. papers

5,832
ext. citations

5.5
avg. IF

5.19
L-index

#	Paper	IF	Citations
160	A randomized controlled trial of a structured program combining aerobic and resistance exercise for adults with type 2 diabetes in Japan.. <i>Diabetology International</i> , 2022 , 13, 75-84	2.3	0
159	The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study.. <i>Advances in Therapy</i> , 2022 , 1	4.1	0
158	Efficacy of education on injection technique for patients diagnosed with diabetes with lipohypertrophy: systematic review and meta-analysis.. <i>BMJ Open</i> , 2022 , 12, e055529	3	0
157	Glucokinase is required for high-starch diet-induced β cell mass expansion in mice. <i>Journal of Diabetes Investigation</i> , 2021 , 12, 1545-1554	3.9	0
156	An evaluation of canagliflozin for the treatment of type 2 diabetes: an update. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 2087-2094	4	1
155	Glucokinase activation or inactivation: Which will lead to the treatment of type 2 diabetes?. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2199-2206	6.7	3
154	The Roles of the IGF Axis in the Regulation of the Metabolism: Interaction and Difference between Insulin Receptor Signaling and IGF-I Receptor Signaling. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
153	Association between ANGPTL3, 4, and 8 and lipid and glucose metabolism markers in patients with diabetes. <i>PLoS ONE</i> , 2021 , 16, e0255147	3.7	1
152	Inverse correlation between serum high-molecular-weight adiponectin and proinsulin level in a Japanese population: The Dynamics of Lifestyle and Neighborhood Community on Health Study. <i>Journal of Diabetes Investigation</i> , 2021 , 12, 63-66	3.9	0
151	A case of an elderly patient with insulin-dependent diabetes and dementia receiving one basal insulin plus one bolus insulin injections a day for 6 months. <i>Diabetology International</i> , 2021 , 12, 135-139	2.3	
150	Relationship between basal sodium intake and the effects of dapagliflozin in albuminuric diabetic kidney disease. <i>Scientific Reports</i> , 2021 , 11, 951	4.9	1
149	Glucokinase Inactivation Paradoxically Ameliorates Glucose Intolerance by Increasing β Cell Mass in Mice. <i>Diabetes</i> , 2021 , 70, 917-931	0.9	6
148	Association of the plasma xanthine oxidoreductase activity with the metabolic parameters and vascular complications in patients with type 2 diabetes. <i>Scientific Reports</i> , 2021 , 11, 3768	4.9	5
147	Asymptomatic meningitis diagnosed by positron emission tomography in a patient with syndrome of inappropriate antidiuretic hormone secretion: a case report. <i>Journal of Medical Case Reports</i> , 2021 , 15, 390	1.2	
146	Efficacy of the Self-management Support System DialBetesPlus for Diabetic Kidney Disease: Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2021 , 10, e31061	2	1
145	Effects of 1-year treatment with canagliflozin on body composition and total body water in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2614-2622	6.7	0
144	Imeglimin ameliorates β cell apoptosis by modulating the endoplasmic reticulum homeostasis pathway. <i>Diabetes</i> , 2021 ,	0.9	3

143	Immediate Glucose-Lowering Effect After the First Administration of Dulaglutide: A Retrospective, Single-Center, Observational Study. <i>Diabetes Therapy</i> , 2021 , 12, 2873-2889	3.6	
142	Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2785-2794	6.7	2
141	Effects of Canagliflozin on Hepatic Steatosis, Visceral Fat and Skeletal Muscle among Patients with Type 2 Diabetes and Non-alcoholic Fatty Liver Disease. <i>Internal Medicine</i> , 2021 , 60, 3391-3399	1.1	1
140	2. How to Select Anti-diabetic Drugs. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2021 , 110, 556-561	0	
139	Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study. <i>Journal of Diabetes Investigation</i> , 2020 , 11, 1248-1257	3.9	3
138	Canagliflozin Increases Calorie Intake in Type 2 Diabetes Without Changing the Energy Ratio of the Three Macronutrients: CANA-K Study. <i>Diabetes Technology and Therapeutics</i> , 2020 , 22, 228-234	8.1	8
137	Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study. <i>Journal of Diabetes Investigation</i> , 2020 , 11, 1542-1550	3.9	3
136	Comparison of Lipid-Lowering Effects of Anagliptin and Miglitol in Patients With Type 2 Diabetes: A Randomized Trial. <i>Journal of Clinical Medicine Research</i> , 2020 , 12, 73-78	2.9	3
135	Potential linkage between dipeptidyl peptidase-4 inhibitor use and the risk of pancreatitis/pancreatic cancer. <i>Journal of Diabetes Investigation</i> , 2020 , 11, 789-791	3.9	1
134	Luseogliflozin increases beta cell proliferation through humoral factors that activate an insulin receptor- and IGF-1 receptor-independent pathway. <i>Diabetologia</i> , 2020 , 63, 577-587	10.3	10
133	Melanophilin Accelerates Insulin Granule Fusion without Predocking to the Plasma Membrane. <i>Diabetes</i> , 2020 , 69, 2655-2666	0.9	5
132	Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 2101-2114	4	1
131	Correlation between serum proinsulin levels and fatty liver: The Dynamics of Lifestyle and Neighborhood Community on Health Study. <i>Journal of Diabetes Investigation</i> , 2020 , 11, 964-970	3.9	0
130	Linagliptin Ameliorates Hepatic Steatosis via Non-Canonical Mechanisms in Mice Treated with a Dual Inhibitor of Insulin Receptor and IGF-1 Receptor. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	3
129	Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22 Suppl 4, 35-47	6.7	1
128	Causes of death and estimated life expectancy among people with diabetes: A retrospective cohort study in a diabetes clinic. <i>Journal of Diabetes Investigation</i> , 2020 , 11, 52-54	3.9	3
127	The effect of long-term past glycemic control on executive function among patients with type 2 diabetes mellitus. <i>Diabetologia International</i> , 2020 , 11, 114-120	2.3	4
126	Proinsulin is sensitive to reflect glucose intolerance. <i>Journal of Diabetes Investigation</i> , 2020 , 11, 75-79	3.9	4

125	Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicentre study: The LixiLan JP-O2 randomized clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2020 , <i>22</i> Suppl 4, 14-23	6.7	7
124	The efficacy and safety of luseogliflozin and sitagliptin depending on the sequence of administration in patients with type 2 diabetes mellitus: a randomized controlled pilot study. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , <i>20</i> , 2185-2194	4	2
123	Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study). <i>Cardiovascular Diabetology</i> , 2019 , <i>18</i> , 110	8.7	15
122	Effect of canagliflozin on the overall clinical state including insulin resistance in Japanese patients with type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2019 , <i>149</i> , 140-146	7.4	18
121	Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice. <i>Metabolism: Clinical and Experimental</i> , 2019 , <i>98</i> , 27-36	12.7	13
120	PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2019 , <i>42</i> , 1724-1732	14.6	128
119	Long-term safety and efficacy of the sodium-glucose cotransporter Δ inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type Δ diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study. <i>Journal of Diabetes Investigation</i> , 2019 , <i>10</i> , 1518-1526	3.9	4
118	Usefulness of antidiabetic alpha-glucosidase inhibitors: a review on the timing of administration and effects on gut hormones. <i>Endocrine Journal</i> , 2019 , <i>66</i> , 395-401	2.9	10
117	Humanistic and economic burden of cardiovascular disease related comorbidities and hypoglycaemia among patients with type 2 diabetes in Japan. <i>Diabetes Research and Clinical Practice</i> , 2019 , <i>149</i> , 115-125	7.4	7
116	Efficacy and Safety of Adding Sitagliptin in Type 2 Diabetes Patients on Insulin: Age-Stratified Comparison at One Year in the ASSIST-K Study. <i>Journal of Clinical Medicine Research</i> , 2019 , <i>11</i> , 311-320	2.9	3
115	The beneficial effects of a muscarinic agonist on pancreatic β cells. <i>Scientific Reports</i> , 2019 , <i>9</i> , 16180	4.9	7
114	Achieving LDL cholesterol target levels. <i>Diabetes, Obesity and Metabolism</i> , 2019 , <i>21</i> , 791-800	6.7	12
113	Aging-like physiological changes in the skin of Japanese obese diabetic patients. <i>SAGE Open Medicine</i> , 2018 , <i>6</i> , 2050312118756662	2.4	7
112	Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study. <i>Diabetes Care</i> , 2018 , <i>41</i> , 1275-1284	14.6	25
111	Prospective observational study in elderly patients with non-valvular atrial fibrillation: Rationale and design of the All Nippon AF In the Elderly (ANAFIE) Registry. <i>Journal of Cardiology</i> , 2018 , <i>72</i> , 300-306 ³		16
110	Serum adiponectin and insulin secretion: A direct or inverse association?. <i>Journal of Diabetes Investigation</i> , 2018 , <i>9</i> , 1106-1109	3.9	20
109	Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS). <i>Diabetes, Obesity and Metabolism</i> , 2018 , <i>20</i> , 1176-1185	6.7	19
108	The role of glucokinase and insulin receptor substrate-2 in the proliferation of pancreatic beta cells induced by short-term high-fat diet feeding in mice. <i>Metabolism: Clinical and Experimental</i> , 2018 , <i>85</i> , 48-58 ^{12.7}		7

107	Safety, tolerability and efficacy of lixisenatide as monotherapy in Japanese patients with type 2 diabetes mellitus: An open-label, multicenter study. <i>Journal of Diabetes Investigation</i> , 2018 , 9, 108-118	3.9	8
106	Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: A randomized controlled trial. <i>Journal of Diabetes Investigation</i> , 2018 , 9, 119-126	3.9	12
105	Impact of Glucose Loading on Variations in CD4 and CD8 T Cells in Japanese Participants with or without Type 2 Diabetes. <i>Frontiers in Endocrinology</i> , 2018 , 9, 81	5.7	6
104	Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Disproportionality Analysis Based on the Japanese Adverse Drug Event Report Database. <i>Diabetes Care</i> , 2018 , 41, e130-e132	14.6	36
103	Effect of Dehydroepiandrosterone (DHEA) on Diabetes Mellitus and Obesity. <i>Vitamins and Hormones</i> , 2018 , 108, 355-365	2.5	16
102	Effect of the sodium-glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages. <i>Scientific Reports</i> , 2018 , 8, 6864	4.9	14
101	Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: A 12-month comparison by concomitant sulphonylurea and/or glinide use. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2541-2550	6.7	3
100	A Randomized Controlled Trial of a Mini Low-Carbohydrate Diet and an Energy-Controlled Diet Among Japanese Patients With Type 2 Diabetes. <i>Journal of Clinical Medicine Research</i> , 2018 , 10, 182-188 ^{2.9}	2.9	5
99	The association of cardiac function, structure, and glycemic control in patients with old myocardial infarction: a study using cardiac magnetic resonance. <i>Diabetology International</i> , 2017 , 8, 23-29	2.3	1
98	Effects of metformin on compensatory pancreatic β cell hyperplasia in mice fed a high-fat diet. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2017 , 313, E367-E380	6	13
97	Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1397-1407	6.7	29
96	Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START-J trial). <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1188-1192	6.7	12
95	Serum Quantitative Proteomic Analysis Reveals Soluble EGFR To Be a Marker of Insulin Resistance in Male Mice and Humans. <i>Endocrinology</i> , 2017 , 158, 4152-4164	4.8	5
94	Factors associated with an inadequate hypoglycemia in the insulin tolerance test in Japanese patients with suspected or proven hypopituitarism. <i>Endocrine Journal</i> , 2017 , 64, 387-392	2.9	1
93	Predicting the ability of elderly diabetes patients to acquire the insulin self-injection technique based on the number of animal names recalled. <i>Journal of Diabetes Investigation</i> , 2017 , 9, 623	3.9	3
92	Metabolic recovery of lipodystrophy, liver steatosis, and pancreatic β cell proliferation after the withdrawal of OSI-906. <i>Scientific Reports</i> , 2017 , 7, 4119	4.9	6
91	Effects of switching to low-dose rosuvastatin (5mg/day) on glucose metabolism and lipid profiles in Japanese patients with type 2 diabetes and dyslipidemia: a single-arm, prospective, interventional trial. <i>Diabetology International</i> , 2017 , 8, 383-391	2.3	0
90	Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus. <i>Journal of Clinical Medicine Research</i> , 2017 , 9, 586-595	2.9	12

89	Effect of Switching From an Anti-Diabetic Loose Dose Combination to a Fixed Dose Combination Regimen at Equivalent Dosage for 6 Months on Glycemic Control in Japanese Patients With Type 2 Diabetes: A Pilot Study. <i>Journal of Clinical Medicine Research</i> , 2017 , 9, 719-724	2.9	2
88	Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study. <i>Journal of Clinical Medicine Research</i> , 2017 , 9, 793-801	2.9	2
87	Evaluation of unmet medical need among Japanese patients with type 2 diabetes mellitus and efficacy of Lixisenatide treatment among Asian type 2 diabetes mellitus patients. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2016 , 10, 23-8	8.9	1
86	Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1995-2003	4	40
85	Differential hepatic distribution of insulin receptor substrates causes selective insulin resistance in diabetes and obesity. <i>Nature Communications</i> , 2016 , 7, 12977	17.4	51
84	Pioglitazone Ameliorates Smooth Muscle Cell Proliferation in Cuff-Induced Neointimal Formation by Both Adiponectin-Dependent and -Independent Pathways. <i>Scientific Reports</i> , 2016 , 6, 34707	4.9	5
83	DPP-4 inhibition improves early mortality, β cell function, and adipose tissue inflammation in db/db mice fed a diet containing sucrose and linoleic acid. <i>Diabetology and Metabolic Syndrome</i> , 2016 , 8, 16	5.6	14
82	Association Between Severe Hypoglycemia and Cardiovascular Disease Risk in Japanese Patients With Type 2 Diabetes. <i>Journal of the American Heart Association</i> , 2016 , 5, e002875	6	40
81	Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study. <i>Journal of Clinical Medicine Research</i> , 2016 , 8, 116-25	2.9	31
80	Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study. <i>Journal of Clinical Medicine Research</i> , 2016 , 8, 373-8	2.9	25
79	Factor Analysis of Changes in Hemoglobin A1c After 12 Months of Sitagliptin Therapy in Patients With Type 2 Diabetes. <i>Journal of Clinical Medicine Research</i> , 2016 , 8, 461-71	2.9	6
78	The Effects of Ramelteon on Glucose Metabolism and Sleep Quality in Type 2 Diabetic Patients With Insomnia: A Pilot Prospective Randomized Controlled Trial. <i>Journal of Clinical Medicine Research</i> , 2016 , 8, 878-887	2.9	14
77	Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study. <i>Cardiovascular Diabetology</i> , 2016 , 15, 134	8.7	21
76	Effect of Switching from Sulphonylurea to Repaglinide Twice or Three Times Daily for 4 Months on Glycemic Control in Japanese Patients with Type 2 Diabetes. <i>Internal Medicine</i> , 2016 , 55, 1697-703	1.1	3
75	Effect of dehydroepiandrosterone (DHEA) on Akt and protein kinase C zeta (PKC ζ) phosphorylation in different tissues of C57BL6, insulin receptor substrate (IRS)1(-/-), and IRS2(-/-) male mice fed a high-fat diet. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016 , 159, 110-20	5.1	9
74	A randomized controlled trial of liraglutide versus insulin detemir plus sitagliptin: Effective switch from intensive insulin therapy to the once-daily injection in patients with well-controlled type 2 diabetes. <i>Journal of Clinical Pharmacology</i> , 2015 , 55, 831-8	2.9	2
73	Anagliptin decreases serum lathosterol level in patients with type 2 diabetes: a pilot study. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 1749-54	4	18
72	Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study. <i>BMC Endocrine Disorders</i> , 2015 , 15, 34	3.3	29

71	Comparison of the administration of teneligliptin every day versus every other day in Japanese patients with type 2 diabetes: a randomized non-inferior test. <i>Journal of Clinical Pharmacology</i> , 2015 , 55, 144-51	2.9	3
70	Early liraglutide treatment improves β cell function in patients with type 2 diabetes: a retrospective cohort study. <i>Endocrine Journal</i> , 2015 , 62, 971-80	2.9	11
69	The Effects of Bazedoxifene on Bone, Glucose, and Lipid Metabolism in Postmenopausal Women With Type 2 Diabetes: An Exploratory Pilot Study. <i>Journal of Clinical Medicine Research</i> , 2015 , 7, 762-9	2.9	10
68	Effects of sitagliptin on the serum creatinine in Japanese type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2015 , 108, e42-5	7.4	8
67	Present status of clinical deployment of glucokinase activators. <i>Journal of Diabetes Investigation</i> , 2015 , 6, 124-32	3.9	60
66	Comparison of Azelnidipine and Trichlormethiazide in Japanese Type 2 Diabetic Patients with Hypertension: The COAT Randomized Controlled Trial. <i>PLoS ONE</i> , 2015 , 10, e0125519	3.7	5
65	Factors Predicting Therapeutic Efficacy of Combination Treatment With Sitagliptin and Insulin in Type 2 Diabetic Patients: The ASSIST-K Study. <i>Journal of Clinical Medicine Research</i> , 2015 , 7, 607-12	2.9	8
64	Effect of repaglinide, administered two or three times daily for 3 months, on glycaemic control in Japanese patients with type 2 diabetes mellitus. <i>Journal of International Medical Research</i> , 2014 , 42, 1150-60	1.4	1
63	Clinical effects of liraglutide on diabetes control in Japanese type 2 diabetes mellitus patients. <i>Diabetology International</i> , 2014 , 5, 98-104	2.3	
62	Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. <i>Cardiovascular Diabetology</i> , 2014 , 13, e5	8.7	135
61	Comparison of intragastric balloon therapy and intensive lifestyle modification therapy with respect to weight reduction and abdominal fat distribution in super-obese Japanese patients. <i>Obesity Research and Clinical Practice</i> , 2014 , 8, e331-8	5.4	16
60	Safety and efficacy of adding sitagliptin to insulin in patients with type 2 diabetes: the ASSIST-K study. <i>Diabetes Research and Clinical Practice</i> , 2014 , 103, e30-3	7.4	11
59	Second-line treatments for dyslipidemia in patients at risk of cardiovascular disease. <i>Endocrine Journal</i> , 2014 , 61, 343-51	2.9	5
58	Using miglitol at 30 min before meal is effective in hyperinsulinemic hypoglycemia after a total gastrectomy. <i>Endocrine Journal</i> , 2014 , 61, 1115-23	2.9	2
57	Effects of miglitol, vildagliptin, or their combination on serum insulin and peptide YY levels and plasma glucose, cholecystokinin, ghrelin, and obestatin levels. <i>Endocrine Journal</i> , 2014 , 61, 249-56	2.9	10
56	Effects of the antitumor drug OSI-906, a dual inhibitor of IGF-1 receptor and insulin receptor, on the glycemic control, β cell functions, and β cell proliferation in male mice. <i>Endocrinology</i> , 2014 , 155, 2102-11	4.8	25
55	Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 749-66	4	65
54	Is a switch from insulin therapy to liraglutide possible in Japanese type 2 diabetes mellitus patients?. <i>Journal of Clinical Medicine Research</i> , 2014 , 6, 138-44	2.9	8

53	Modification of a simple clinical scoring system as a diagnostic screening tool for non-alcoholic steatohepatitis in Japanese patients with non-alcoholic fatty liver disease. <i>Journal of Diabetes Investigation</i> , 2013 , 4, 651-8	3.9	9
52	Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. <i>BMJ, The</i> , 2013 , 347, f4533	5.9	331
51	Lessons from mouse models of high-fat diet-induced NAFLD. <i>International Journal of Molecular Sciences</i> , 2013 , 14, 21240-57	6.3	115
50	Glycemic control after addition of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes showing inadequate response to thrice-a-day treatment with α -glucosidase inhibitors. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 1111-8	4	5
49	Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2013 , 4, 571-5	3.9	14
48	Mosapride citrate, a 5-HT ₄ receptor agonist, increased the plasma active and total glucagon-like peptide-1 levels in non-diabetic men. <i>Endocrine Journal</i> , 2013 , 60, 493-499	2.9	8
47	Comparison of plasma active glucagon-like peptide-1 (GLP-1) levels assayed with or without plasma extraction in non-diabetic men. <i>Endocrine Journal</i> , 2012 , 59, 435-8	2.9	4
46	Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients. <i>Journal of Diabetes Investigation</i> , 2012 , 3, 503-9	3.9	35
45	The safety, efficacy and predictors for HbA _{1c} reduction of sitagliptin in the treatment of Japanese type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2012 , 95, e20-2	7.4	56
44	Migliitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin. <i>Acta Diabetologica</i> , 2012 , 49, 225-30	3.9	31
43	Effects of liraglutide on β -cell-specific glucokinase-deficient neonatal mice. <i>Endocrinology</i> , 2012 , 153, 3066-75	4.8	19
42	Cross-sectional survey of diabetic neuropathy in Kanagawa and clinical significance of a touch test using tissue paper. <i>Journal of Diabetes Investigation</i> , 2012 , 3, 252-8	3.9	4
41	Effect of Acarbose Therapy Once or Twice a Day on Glycemic Control in Japanese Patients with Type 2 Diabetes. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2012 , 43, 17-20	0	2
40	Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients. <i>Journal of Clinical Medicine Research</i> , 2012 , 4, 309-13	2.9	37
39	Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. <i>Diabetes</i> , 2011 , 60, 1246-57	0.9	198
38	Effect of long-term treatment with a small-molecule glucokinase activator on glucose metabolism, lipid profiles and hepatic function. <i>Journal of Diabetes Investigation</i> , 2011 , 2, 276-9	3.9	10
37	Effects of miglitol taken just before or after breakfast on plasma glucose, serum insulin, glucagon and incretin levels after lunch in men with normal glucose tolerance, impaired fasting glucose or impaired glucose tolerance. <i>Journal of Diabetes Investigation</i> , 2011 , 2, 435-40	3.9	14
36	Impact of glucose tolerance on the severity of non-alcoholic steatohepatitis. <i>Journal of Diabetes Investigation</i> , 2011 , 2, 483-9	3.9	8

35	Time-course of changes of visceral fat area, liver volume and liver fat area during intragastric balloon therapy in Japanese super-obese patients. <i>Internal Medicine</i> , 2011 , 50, 2449-55	1.1	12
34	Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet. <i>Metabolism: Clinical and Experimental</i> , 2011 , 60, 617-28	12.7	46
33	Protective effects of dipeptidyl peptidase-4 (DPP-4) inhibitor against increased β cell apoptosis induced by dietary sucrose and linoleic acid in mice with diabetes. <i>Journal of Biological Chemistry</i> , 2011 , 286, 25467-76	5.4	42
32	Self-injection of insulin using appropriate supportive devices in handicapped subjects with diabetes. <i>Diabetes Technology and Therapeutics</i> , 2010 , 12, 483-90	8.1	2
31	Relationship between urinary sodium excretion and pioglitazone-induced edema. <i>Journal of Diabetes Investigation</i> , 2010 , 1, 208-11	3.9	115
30	Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study. <i>Hepatology Research</i> , 2010 , 40, 566-73	5.1	100
29	Correlations of fasting and postprandial blood glucose increments to the overall diurnal hyperglycemic status in type 2 diabetic patients: variations with levels of HbA1c. <i>Endocrine Journal</i> , 2010 , 57, 259-66	2.9	25
28	Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15,652 patients. <i>Endocrine Journal</i> , 2010 , 57, 499-507	2.9	30
27	Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men. <i>Endocrine Journal</i> , 2010 , 57, 667-72	2.9	41
26	Comparison of adverse gastrointestinal effects of acarbose and miglitol in healthy men: a crossover study. <i>Internal Medicine</i> , 2010 , 49, 1085-7	1.1	18
25	Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide levels in healthy men. <i>Endocrine Journal</i> , 2010 , 57, 673-7	2.9	17
24	Comparison of pre- versus post-meal administration of voglibose in men with or without impaired glucose tolerance. <i>Diabetes Research and Clinical Practice</i> , 2009 , 83, e31-2	7.4	9
23	Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2009 , 51, 548-56	13.4	69
22	Impact of small-molecule glucokinase activator on glucose metabolism and beta-cell mass. <i>Endocrinology</i> , 2009 , 150, 1147-54	4.8	56
21	Role of the liver in glucose homeostasis in PI 3-kinase p85 α -deficient mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009 , 296, E842-53	6	9
20	Effect of dehydroepiandrosterone on atherosclerosis in apolipoprotein E-deficient mice. <i>Journal of Atherosclerosis and Thrombosis</i> , 2009 , 16, 501-8	4	9
19	Dynamic functional relay between insulin receptor substrate 1 and 2 in hepatic insulin signaling during fasting and feeding. <i>Cell Metabolism</i> , 2008 , 8, 49-64	24.6	172
18	Hypoadiponectinemia plays a crucial role in the development of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus independent of visceral adipose tissue. <i>Alcoholism: Clinical and Experimental Research</i> , 2007 , 31, S15-21	3.7	29

17	Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage. <i>Journal of Gastroenterology</i> , 2007 , 42, 375-81	6.9	68
16	Divided-dose administration of miglitol just before and 15 minutes after the start of a meal smoothes postprandial plasma glucose excursions and serum insulin responses in healthy men. <i>Endocrine Journal</i> , 2007 , 54, 1009-14	2.9	15
15	Administration of miglitol until 30 min after the start of a meal is effective in type 2 diabetic patients. <i>Diabetes Research and Clinical Practice</i> , 2007 , 78, 30-3	7.4	27
14	Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. <i>Journal of Clinical Investigation</i> , 2007 , 117, 246-57	15.9	262
13	Serum ferritin is associated with visceral fat area and subcutaneous fat area. <i>Diabetes Care</i> , 2005 , 28, 2486-91	14.6	100
12	Increased serum leptin protects from adiposity despite the increased glucose uptake in white adipose tissue in mice lacking p85alpha phosphoinositide 3-kinase. <i>Diabetes</i> , 2004 , 53, 2261-70	0.9	15
11	Insulin receptor substrate 2 plays a crucial role in beta cells and the hypothalamus. <i>Journal of Clinical Investigation</i> , 2004 , 114, 917-27	15.9	187
10	Impact of genetic background and ablation of insulin receptor substrate (IRS)-3 on IRS-2 knock-out mice. <i>Journal of Biological Chemistry</i> , 2003 , 278, 14284-90	5.4	23
9	Insights into molecular pathogenesis of type 2 diabetes from knockout mouse models. <i>Endocrine Journal</i> , 2002 , 49, 247-63	2.9	13
8	Subcellular localization of insulin receptor substrate family proteins associated with phosphatidylinositol 3-kinase activity and alterations in lipolysis in primary mouse adipocytes from IRS-1 null mice. <i>Diabetes</i> , 2001 , 50, 1455-63	0.9	18
7	Antibody-mediated insulin resistance treated by cessation of insulin administration. <i>Internal Medicine</i> , 2000 , 39, 143-5	1.1	15
6	Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. <i>Nature Genetics</i> , 1999 , 21, 230-5	36.3	348
5	Involvement of p85 in p53-dependent apoptotic response to oxidative stress. <i>Nature</i> , 1998 , 391, 707-10	50.4	151
4	Germ-line contribution of embryonic stem cells in chimeric mice: influence of karyotype and in vitro differentiation ability. <i>Experimental Animals</i> , 1997 , 46, 17-23	1.8	30
3	Approach to the Pathogenesis of Non-Insulin-Dependent Diabetes Mellitus by Gene Targeting.. <i>Proceedings of the Japanese Society of Animal Models for Human Diseases</i> , 1997 , 13, 75-78		
2	Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. <i>Nature</i> , 1994 , 372, 182-6	50.4	914
1	The Role of Phosphoinositide-3-kinase in Mast Cell Homing to the Gastrointestinal Tract. <i>Novartis Foundation Symposium</i> , 152-165		4